SCHEMBL6086280

SCHEMBL6086280

CC(C(=O)Nc1cccc(-c2n[nH]cc2-c2nc3cc(C(C)(C)C)ccc3o2)c1)c1ccc(Cl)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.45
USP2 O75604 1/20 0.45
POLB P06746 1/20 0.45
RXFP1 Q9HBX9 1/20 0.44
MAPT P10636 2/20 0.43
MEN1 O00255 1/20 0.43
NPC1 O15118 1/20 0.43
ALDH1A1 P00352 1/20 0.43
GAA P10253 1/20 0.43
HPGD P15428 1/20 0.43
RAB9A P51151 1/20 0.43
KMT2A Q03164 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
TP53 P04637 3/20 0.43
P2RY14 Q15391 3/20 0.43
LMNA P02545 2/20 0.43
CASP3 P42574 1/20 0.42
SENP7 Q9BQF6 1/20 0.42
MAOA P21397 1/20 0.41
ADRA1A P35348 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6084520 0.82 MAPT (0.46) KDM4EPOLBRXFP1MAPTMEN1
SCHEMBL6085891 0.82 HSD17B10 (0.47) KDM4EUSP2POLBRXFP1MAPT
SCHEMBL6085071 0.81 CASP3 (0.52) KDM4EPOLBMAPTNPC1ALDH1A1
SCHEMBL6085604 0.80 P2RY14 (0.55) KDM4EUSP2POLBMAPTALDH1A1
SCHEMBL6086111 0.80 RXFP1 (0.51) POLBRXFP1MAPTNPC1RAB9A
SCHEMBL6083799 0.80 HSD17B10 (0.48) KDM4EUSP2POLBRXFP1MAPT
SCHEMBL6086607 0.79 P2RY14 (0.51) KDM4EUSP2POLBMAPTMEN1
SCHEMBL6085471 0.79 MAPT (0.44) KDM4EUSP2POLBRXFP1MAPT
SCHEMBL6085988 0.79 CETP (0.44) KDM4EPOLBRXFP1MAPTNPC1
SCHEMBL6084626 0.79 KDM4E (0.59) KDM4EUSP2POLBRXFP1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US claimed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP claimed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US claimed
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US disclosed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP disclosed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US disclosed
EP-1377589-A1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-01-07 EP disclosed
WO-2002062804-A1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2002-08-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors MAP3K15, MAP3K20, MAP3K3 KDM4E 1175/4885USP2 2427/4885POLB 1679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.